Navigation Links
PharMEDium Announces National Rollout of Electronic 222 Ordering Initiative
Date:6/26/2008

HUNDREDS OF CUSTOMER HOSPITALS USING ELECTRONIC 222 TO ORDER CLASS II

CONTROLLED SUBSTANCES

SEATTLE, June 9 /PRNewswire/ -- PharMEDium Services, LLC, the leading provider of outsourced hospital pharmacy I.V. compounded solutions, has expanded its first-in-the-industry electronic 222 (e-222) ordering initiative, which enables virtually real-time ordering of Schedule II Controlled Substances versus the more time-consuming traditional process, to all hospitals nationwide.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051202/PHARMEDIUMLOGO)

The company announced the initiative at the American Society of Health-System Pharmacists' Summer Meeting and exhibition here.

Hundreds of customers are now ordering pain management medications through PharMEDium's e-222 system, which applies to the entire line of its pain management services. "Our expansion of e-222 represents an ongoing commitment to patient safety, quality, and superior customer service. The early and fast adoption by our customers represents their partnership with us in helping make e-222 a standard practice across our industry," said David Jonas, PharMEDium's Chairman and Chief Executive Officer.

PharMEDium's new controlled substance ordering system aligns with the efforts of the U.S. Drug Enforcement Administration (DEA) and drug industry leaders to take advantage of e-commerce tools to improve efficiency and effectiveness associated with controlled substances ordering. DEA requires a Form 222 for all orders of Schedule II Controlled Substances, which until recently could only be processed through paper forms. E-222 ordering takes about 20 seconds, versus about 20 minutes for paper orders, according to DEA's Office of Diversion Control (ODC). In addition, the elimination of the paper Form 222 reduces the time it takes to receive an order by one to two days. Hospitals interested in e-222 must obtain a digital certificate from the DEA to participate, which typically takes 30 days from application to approval.

"E-222 ordering has significant benefits," said Susan Groth, Pharmacy Buyer at Methodist Hospital in St. Louis Park, MN. "This initiative makes the ordering process faster and easier, in addition to reducing errors and rework," Groth added.

"E-222 is one element of PharMEDium's online customer service offering available on the company's website," Jonas said. "In addition to online ordering, PharMEDium's customers can obtain order status information, track shipments, and review invoice history at pharmedium.com. These value-added features were developed based on extensive customer feedback and provide a multitude of time- and resource-saving benefits. PharMEDium is committed to deploying new and innovative online functionality to provide our customers with world-class customer service," Jonas added.

About PharMEDium Services, LLC

For more than 15 years, PharMEDium has been the leading provider of outsourced compounding services. In that time, PharMEDium has grown into a nationwide network of state licensed and federally registered compounding centers providing trusted solutions to more than 1,800 hospitals throughout the United States. Managed by licensed pharmacists and staffed by certified technicians, the company complies with all applicable state laws and FDA regulations, including USP Chapter < 797 > and DEA requirements.

Contact: Amy Langan, MEDIA INQUIRIES: Jon Ross,

PharMEDium Director of Marketing Ross Consulting &

847/457-2327 Communications

Email: info@pharmedium.com 773-271-0677

jross1chi@prodigy.net


'/>"/>
SOURCE PharMEDium Services, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology news :

1. March of Dimes announces Prematurity Campaign expansion at Surgeon Generals conference
2. TAU announces new supercenter for renewable energy
3. Ecological Society of America announces its 93rd Annual Meeting
4. Neurotechnology Announces MegaMatcher 2.1 SDK for Development of Large-scale AFIS and Multi-biometric Face-Fingerprint Identification Systems
5. BIO-key(R) Announces First Quarter 2008 Earnings Release and Conference Call Schedule
6. Autism Speaks announces multinational initiative
7. Aware Announces Q1 2008 Earnings Conference Call
8. The Alliance for Lupus Research announces 2008 grantees
9. Titanium Group Announces Contract for Security Solution in High-End Residentials
10. National Lung Cancer Partnership announces winner of 2007 Career Development Award
11. BIO-key(R) Announces Fourth Quarter and Full Year 2007 Earnings Release and Conference Call Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
Breaking Biology Technology: